



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/11/10
(87) Date publication PCT/PCT Publication Date: 2019/05/23
(85) Entrée phase nationale/National Entry: 2020/05/01
(86) N° demande PCT/PCT Application No.: IB 2018/058848
(87) N° publication PCT/PCT Publication No.: 2019/097381
(30) Priorités/Priorities: 2017/11/17 (IN201741041231);
2018/08/29 (IN201841032406)

(51) Cl.Int./Int.Cl. *C07D 339/02* (2006.01),
A61K 31/381 (2006.01), *A61K 31/439* (2006.01),
A61K 31/4409 (2006.01), *A61K 31/498* (2006.01),
A61P 17/00 (2006.01), *A61P 27/02* (2006.01),
C07D 213/40 (2006.01), *C07D 403/12* (2006.01),
C07D 453/02 (2006.01)
(71) Demandeur/Applicant:
CELLIX BIO PRIVATE LIMITED, IN
(72) Inventeur/Inventor:
KANDULA, MAHESH, IN
(74) Agent: BLAKE, CASSELS & GRAYDON LLP

(54) Titre : COMPOSES, COMPOSITIONS ET METHODES POUR LE TRAITEMENT DE TROUBLES OCULAIRES ET DE MALADIES CUTANÉES
(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS AND SKIN DISEASES

(57) **Abrégé/Abstract:**

Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associated therewith. Also disclosed is a pharmaceutical composition comprising as an active ingredient at least one compound of formula I and a pharmaceutically acceptable excipient. Also disclosed is a method of treating an eye disorder, skin disease and/or a complication thereof in a subject in need thereof by administering at least one compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 May 2019 (23.05.2019)(10) International Publication Number
WO 2019/097381 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) A61K 31/385 (2006.01)

(21) International Application Number:

PCT/IB2018/058848

(22) International Filing Date:

10 November 2018 (10.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201741041231 17 November 2017 (17.11.2017) IN
201841032406 29 August 2018 (29.08.2018) IN(71) Applicant: **CELLIX BIO PRIVATE LIMITED** [IN/IN];
Plot No. 1177 B, Road No. 56, Jubilee Hills, Hyderabad,
Telangana 500 081 (IN).(72) Inventor: **KANDULA, Mahesh**; 11-61, G Medapadu, Sa-
malkot Mandal, Andhra Pradesh 533434 (IN).(74) Agent: **KHURANA & KHURANA, ADVOCATES &
IP ATTORNEYS**; E-13, UPSIDC, Site-IV, Behind-Grand
Venice, Kasna Road, Greater Noida, National Capital Re-
gion, Uttar Pradesh 201310 (IN).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS AND SKIN DISEASES

(57) Abstract: Disclosed is a compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof, which is useful for treatment of eye disorders, skin diseases and/or complications associated therewith. Also disclosed is a pharmaceutical composition comprising as an active ingredient at least one compound of formula I and a pharmaceutically acceptable excipient. Also disclosed is a method of treating an eye disorder, skin disease and/or a complication thereof in a subject in need thereof by administering at least one compound of formula I or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.



WO 2019/097381 A1

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS AND SKIN DISEASES

PRIORITY

[0001] The present application claims benefit of Indian Provisional Application Nos. IN201741041231 filed on 17th November 2017 and IN201841032406 filed on 29th August 2018, the contents of which are incorporated in its entirety herein by reference.

FIELD OF THE INVENTION

[0002] The present disclosure relates to novel compounds for treatment of eye disorders, skin diseases and complications associated therewith, and pharmaceutical compositions comprising such compounds. The present disclosure also relates to methods of treating an eye disorder and skin disease or a complication thereof in a subject in need thereof.

BACKGROUND OF THE INVENTION

[0003] Age-related eye diseases, in many cases are not sudden but tend to develop slowly as a person ages. Of the many age-related eye diseases, there are four major ones that are recognized and that can be detected and treated if a comprehensive eye examination is performed. These four age-related eye diseases are Macular Degeneration, Cataracts, Glaucoma and Diabetic Retinopathy are expected to dramatically increases if left untreated can cause serious vision loss and blindness. Populations are most at risk for developing eye disease is unaware of the factors that make them susceptible.

[0004] Diseases of the eye leading to blindness are almost exclusively a function of ageing. As the proportion of the elderly population increases around the world, the prevalence and effects of age-related eye diseases are also increasing. The leading causes of blindness and low vision are primarily age-related eye diseases such as age-related macular degeneration, cataract, diabetic retinopathy, and glaucoma. Age-related cataract will become an even larger percentage of the causes of blindness worldwide, and glaucoma and age-related macular degeneration will emerge as public health issues.

[0005] Most common eye problems include Refractive errors, Cataracts - clouded lenses, Optic nerve disorders, including glaucoma, Retinal disorders - problems with the nerve layer at the

back of the eye, Macular degeneration - a disease that destroys sharp, central vision, Diabetic eye problems and Conjunctivitis - an infection also known as pinkeye.

[0006] Presbyopia is the progressive loss of accommodation resulting in loss of the visual ability to focus on objects located at different distances. Accommodation in humans is performed by ciliary muscle and iris sphincter contractions, convergence and changes in the shape and position of the lens. The latter action is passive, meaning that the lens changes are dependent on the ciliary muscle and iris contractions. Also, when the centre of the accommodation is active, the ciliary muscle contraction is stimulated and miosis and convergence occurs in normal binocular patients.

[0007] Haematopoietic stem cell transplantation (SCT) is an established and potentially curative treatment modality for various malignant and non-malignant haematologic diseases. Unfortunately, patients treated with allo-SCT often develop graft-versus-host disease (GVHD), a potentially life-threatening multi-organ systemic disease associated with significant morbidity and mortality. Ocular GVHD (oGVHD) affects 40–60% of patients treated with allo-SCT. Although oGVHD may be the only manifestation of GVHD, it is more frequently seen together with other systemic manifestations and 50–90% of patients with systemic GVHD also have oGVHD.

[0008] Typically, oGVHD involves the anterior segment of the eye, including the lid, lacrimal gland, conjunctiva and cornea. Clinically, the condition manifests primarily as dry eye disease (DED), with keratoconjunctivitis sicca (KCS), and resembles the clinical findings seen in other immunologically mediated inflammatory diseases of the ocular surface. DED is defined as a ‘disorder of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort’. Although DED can occur without keratitis, the terms DED and KCS are often used interchangeably. Patients with DED usually experience symptoms such as redness, photophobia, foreign body sensation, excessive tearing, discharge, blurring of vision and pain. The ocular surface affliction is irreversible in many cases and patients often experience a significant reduction in quality of life.

[0009] Keratoconjunctivitis sicca, more commonly known as dry eye, is an extremely common and often unrecognized disease. It is the condition in ophthalmology that in its mild grade of severity will affect most of the population at one time or other. Due to a wide variety of presentations and symptoms, it often frustrates the ophthalmologists as well as patients. Due to multifactorial and elusive etiology, it is often challenging to treat dry eye. Ocular surface disorders are also clinically important to treat especially in terms of visual acuity. Xerodacryology is therefore becoming a very important branch of ophthalmology. Recent studies have given insight into the inflammatory etiology of dry eye. The conventional and main approach to the treatment of dry eye is providing lubricating eye drops or tear substitutes. However, the newer treatment approach is to target the underlying cause of dry eye instead of conventional symptomatic relief.

[0010] Cataract still is a leading cause of visual impairment worldwide. Despite the fact that 90% of cataracts in the world are reported in developing countries, its social, physical and economic impact is still substantial in the developed world. Cataract is a common cause of visual impairment in the elderly that is often noticed by patients at an early stage, and surgery is often effective in restoring vision. Nevertheless, cataract surgery still remains a major healthcare cost in Asia, Europe and other Western countries. Progressive ageing of the European population is linked to the increase of incidence and prevalence of cataract. Therefore, a review of modifiable risk factors of cataract and the evaluation of aspects that affect total costs of cataract surgeries is needed. Cataract is a multifactorial disease associated with age, female sex, genetic predisposition, smoking, diabetes mellitus, drug intake and environmental exposure to UVB radiation.

[0011] Rosacea is a common chronic relapsing inflammatory skin condition which mostly affects the central face, with women being more affected than men. The pathophysiology is not completely understood, but dysregulation of the immune system, as well as changes in the nervous and the vascular system have been identified. Symptoms are initially transient. This is followed by persistent erythema due to repeated vasodilation, then telangiectasia and skin inflammation in the form of papules, pustules, lymphoedema and fibrosis. Rosacea can seriously affect a patient's quality of life. This should prompt clinicians to diagnose it early and start treatment.


[0012] Rosacea can be a challenging condition to treat. Tailoring therapies to the type of rosacea is an important part of management.

[0013] Managing acute pathology of often relies on the addressing underlying pathology and symptoms of the disease. There is currently a need in the art for new compositions to treatment or delay of the onset of eye disorders, skin diseases and its associated complications progression.

SUMMARY OF THE INVENTION

[0014] The present disclosure provides compounds, compositions containing these compounds and methods of using the same to treat eye disorders and skin diseases and complications associated therewith.


[0015] In one aspect, the present disclosure provides a compound of formula I










Formula I


or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein, X⁺ represents,










[0016] The compound of formula I of the present disclosure is useful for the treatment of eye disorders, skin diseases and complications associated therewith. The eye disorder that can be treated by the compound of formula I of the present disclosure includes macular degeneration, cataract, ocular graft versus host disease (oGVHD), glaucoma, diabetic retinopathy, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia. The skin diseases that can be treated by the compound of formula I of the present disclosure include rosacea, flushing, acne, psoriasis and inflammatory skin conditions.

[0017] In an embodiment, the compound of formula I has a structure according to formula Ia




Formula Ia

or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein X^+ is as defined above for the compound of formula I.

[0018] In another embodiment, the compound of formula I has a structure according to formula Ib








Formula Ib






or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,






wherein X^+ is as defined above for the compound of formula I.


[0019] In an exemplary embodiment, the compound of formula I can have one of the following structures:











[0020] Another aspect of the present disclosure is directed to a pharmaceutical composition for treating an eye disorder, skin disease or complications thereof, the composition comprising at least one compound selected from compounds of formula I, formula Ia and formula Ib, or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof and at least one pharmaceutically acceptable excipient. In an embodiment, the pharmaceutical composition is formulated for oral, nasal, ocular, topical, ointment, cream, paste, spray, rectal, vaginal, aerosol or parenteral administration to a subject. In certain preferred embodiments, the pharmaceutical composition is a topical ophthalmic formulation. In certain preferred embodiments, the pharmaceutical composition is an ophthalmic drop formulation, gel, viscosity imparting agent, ointment, aqueous suspension and intraocular ophthalmic formulation. In another certain preferred embodiments, the pharmaceutical composition is a dermal formulation, gel, cream, ointment, spray, aqueous

solution, patches, paste, foams, lotions, liniments, and transdermal formulation. In certain preferred embodiments, the pharmaceutical composition is a dermal formulation.

[0021] Another aspect of the present disclosure is directed to a method of treating an eye disorder or a complication thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula I disclosed herein or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof. In an embodiment, the eye disorder that can be treated by the method disclosed herein can include macular degeneration, cataract, ocular graft versus host disease (oGVHD), glaucoma, ocular redness, ocular hypertension, ocular irritation, diabetic retinopathy, dry eye, ocular neuritis, allergic conjunctivitis, hyperemia, posterior capsule opacification, corneal edema visual acuity, rhegmatogenous macula-off retinal detachment, retinitis pigmentosa and presbyopia.

[0022] Another aspect of the present disclosure is directed to a method of treating skin disease or a complication thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula I disclosed herein or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof. In an embodiment, the skin disease that can be treated by the method disclosed herein can include rosacea, hand-foot syndrome, acne rosacea, capillary malformations, telangiectasias, flushing, acne, erythema rosacea, chronic persistent vascular facial erythema, psoriasis and any inflammatory skin conditions.

[0023] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIG. 1 shows ^1H NMR spectrum of compound CLX-G162-C01.

[0025] FIG. 2 shows a partial magnification of ^1H NMR spectrum of compound CLX-G162-C01.

[0026] FIG. 3 shows a partial magnification of ^1H NMR spectrum of compound CLX-G162-C01.

[0027] FIG. 4 shows ^1H NMR spectrum and its partial magnification of compound CLX-G162-C02.

[0028] FIG. 5 shows ^1H NMR spectrum and its partial magnification of compound CLX-G162-C02.

[0029] FIG. 6 shows ^1H NMR spectrum and its partial magnification of compound CLX-G162-C02.

[0030] FIG. 7 shows ^1H NMR spectrum of compound CLX-G162-C03.

[0031] FIG. 8 shows a partial magnification of ^1H NMR spectrum of compound CLX-G162-C03.

[0032] FIG. 9 shows a partial magnification of ^1H NMR spectrum of compound CLX-G162-C03.

DETAILED DESCRIPTION OF THE INVENTION

[0033] The following is a detailed description of embodiments of the disclosure depicted in the accompanying drawings. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.

[0034] Each of the appended claims defines a separate invention, which for infringement purposes is recognized as including equivalents to the various elements or limitations specified in the claims. Depending on the context, all references below to the “invention” may in some cases refer to certain specific embodiments only. In other cases, it will be recognized that references to the “invention” will refer to subject matter recited in one or more, but not necessarily all, of the claims.

[0035] As used in the description herein and throughout the claims that follow, the meaning of “a,” “an,” and “the” includes plural reference unless the context clearly dictates otherwise. Also,

as used in the description herein, the meaning of “in” includes “in” and “on” unless the context clearly dictates otherwise.

[0036] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0037] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.

[0038] As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.

[0039] The term "isomers" as used herein throughout the present disclosure encompasses within its meaning, the compounds that have same molecular formula but differ in the nature or sequence of bonding of their atoms or arrangement of their atoms in space.

[0040] The term "stereoisomer" as used herein throughout the present disclosure encompasses within its meaning, isomers that differ in the arrangement of their atoms in space.

[0041] The term "diastereomer" as used herein throughout the present disclosure encompasses within its meaning, stereoisomers with opposite configuration at one or more chiral centers, which are not enantiomers.

[0042] The term "enantiomer" as used herein throughout the present disclosure encompasses within its meaning, stereoisomers bearing one or more asymmetric centers that are non-superimposable mirror images of each other. When a compound has one asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center or centers and is described by the R- and S-sequencing rules of Cahn, Ingold and Prelog (CIP), or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can

exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

[0043] As used herein, the term "metabolic condition" refers to an Inborn errors of metabolism (or genetic metabolic conditions) are genetic disorders that result from a defect in one or more metabolic pathways; specifically, the function of an enzyme is affected and is either deficient or completely absent.

[0044] The term "polymorph" as used herein is art-recognized and refers to one crystal structure of a given compound.

[0045] The phrases "parenteral administration" and "administered parenterally" as used herein refer to modes of administration other than enteral and topical administration, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradental, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0046] A "patient," "subject," or "host" to be treated by the subject method may mean either a human or non-human animal, such as primates, mammals, and vertebrates.

[0047] The phrase "pharmaceutically acceptable" is art-recognized. In certain embodiments, the term includes compositions, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0048] The phrase "pharmaceutically acceptable excipient" is art-recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of a subject composition and not injurious to the patient. In certain embodiments, a pharmaceutically acceptable carrier is non-pyrogenic. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives,

such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0049] The term "prodrug" is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal.

[0050] The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).

[0051] The term "predicting" as used herein refers to assessing the probability related diseases patient will suffer from abnormalities or complication and/or terminal platelet aggregation or failure and/or death (i.e. mortality) within a defined time window (predictive window) in the future. The mortality may be caused by the central nervous system or complication. The predictive window is an interval in which the subject will develop one or more of the said complications according to the predicted probability. The predictive window may be the entire remaining lifespan of the subject upon analysis by the method of the present invention.

[0052] The term "treating" is art recognized and includes preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or

condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected, such as treating disorders of eyelid, dry eye, oGVHD, retinitis pigmentosa, lacrimal system and orbit, disorders of conjunctiva, disorders of sclera, cornea, iris and ciliary body, disorders of lens, disorders of choroid and retina, glaucoma, disorders of vitreous body and globe, disorders of optic nerve and visual pathways, visual disturbances and blindness, presbyopia and skin diseases such as rosacea, flushing, acne, psoriasis and any inflammatory skin conditions and other related diseases or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.

[0053] The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a solvate or hydrate or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time. The effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.

[0054] As used herein, the term "ophthalmic composition" refers to a composition intended for application to the eye or its related or surrounding tissues such as, for example, the eyelid or onto the cornea. The term also includes compositions intended to therapeutically treat conditions of the eye itself or the tissues surrounding the eye. The ophthalmic composition can be applied topically or by other techniques, as known to or appreciated by persons skilled in the pertinent art, such as injection to the eye. Examples of suitable topical administration to the eye include administration in form of eye drops and by spray formulations. A further suitable

topical administration route is by subconjunctival injection. The compositions can also be provided to the eye periocularly or retro-orbitally.

[0055] In certain embodiments, the pharmaceutical compositions described herein are formulated in a manner such that said compositions will be delivered to a patient in a therapeutically effective amount, as part of a prophylactic or therapeutic treatment. The desired amount of the composition to be administered to a patient will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the hydrates or solvates and compositions from the subject compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.

[0056] Additionally, the optimal concentration and/or quantities or amounts of any particular solvate or hydrate or composition may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.

[0057] In certain embodiments, the dosage of the compounds of Formula I provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum plasma concentration (C_{max}) and the area under the plasma concentration-time curve from time 0 to infinity may be used.


[0058] When used with respect to a pharmaceutical composition or other material, the term "sustained release" is art-recognized. For example, a subject composition which releases a substance over time may exhibit sustained release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one time. For example, in particular embodiments, upon contact with body fluids including blood, spinal fluid, mucus secretions, lymph or the like, one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis) with concomitant release of any material incorporated therein, e.g., an therapeutic and/or

biologically active solvate or hydrate and/or composition, for a sustained or extended period (as compared to the release from a bolus). This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.

[0059] The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” are art-recognized, and include the administration of a subject composition, therapeutic or other material at a site remote from the disease being treated. Administration of an agent for the disease being treated, even if the agent is subsequently distributed systemically, may be termed “local” or “topical” or “regional” administration, other than directly into the central nervous system, e.g., by subcutaneous administration, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes.

[0060] The present disclosure also contemplates prodrugs of the compounds disclosed herein, as well as pharmaceutically acceptable hydrates or solvates of said prodrugs.


[0061] In one aspect, there is provided a compound with structure of formula I





Formula I


or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,


wherein, X^+ represents,












[0062] The compound of formula I of the present disclosure is useful for the treatment of eye disorder, skin disease and complications associated therewith. The eye disorder that can be treated by the compound of formula I of the present disclosure includes macular degeneration, cataract, ocular graft versus host disease (oGVHD), ocular redness, ocular irritation, glaucoma, diabetic retinopathy, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia. The skin disease that can be treated by the compound of formula I of the present disclosure includes rosacea, flushing, acne, psoriasis and any inflammatory skin conditions.

[0063] In an embodiment, the compound of formula I has a structure according to formula Ia




Formula Ia

or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein X^+ is as defined above for the compound of formula I.

[0064] In another embodiment, the compound of formula I has a structure according to formula Ib



Formula Ib

or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein X^+ is as defined above for the compound of formula I.

[0065] Another aspect of the present disclosure is directed to a pharmaceutical composition for treating an eye disorder, skin disease or complications thereof, which comprises at least one compound selected from compounds of formula I, formula Ia and formula Ib, or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof and at least one pharmaceutically acceptable excipient. In an embodiment, the pharmaceutical composition is formulated for oral, dermal, nasal, ocular, topical, rectal, vaginal, aerosol or parenteral administration to a subject. In certain preferred embodiments, the pharmaceutical composition is a topical ophthalmic formulation or a dermal

formulation. In certain preferred embodiments, the pharmaceutical composition is an ophthalmic drop formulation, gel, viscosity imparting agent, ointment, aqueous suspension, intraocular ophthalmic formulation, dermal formulation, gel, cream, paste, ointment, spray, aqueous solution, patches, foams, lotions, liniments and transdermal formulation.

[0066] Another aspect of the present disclosure is directed to a method of treating an eye disorder or a complication thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula I disclosed herein or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof. In an embodiment, the eye disorder that can be treated by the method disclosed herein can include macular degeneration, cataract, ocular graft versus host disease (oGVHD), ocular redness, ocular irritation, glaucoma, diabetic retinopathy, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia. In an embodiment, the compound of formula I can be administered to said subject in combination with a pharmaceutically acceptable excipient. In an embodiment, the therapeutically effective amount of the compound of formula I that can be administered to said subject can range from 0.0001mg to 1000mg. In an embodiment, the compound of formula I can be administered topically to at least one eye of a subject in need of treatment for eye disorder or complications associated therewith.

[0067] In an embodiment, the eye disorder that can be treated by the method disclosed herein can include macular degeneration, ocular graft versus host disease (oGVHD), cataract, glaucoma, diabetic retinopathy, ocular redness, ocular irritation, dry eye, ocular neuritis, retinitis pigmentosa and presbyopia.

[0068] Another aspect of the present disclosure is directed to a method of treating a skin disease or a complication thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of formula I disclosed herein or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof. In an embodiment, the skin disease that can be treated by the method disclosed herein can include rosacea, flushing, acne, psoriasis and any inflammatory skin conditions. In an embodiment, the compound of formula I can be administered to said subject in combination with a pharmaceutically acceptable excipient. In an embodiment, the

therapeutically effective amount of the compound of formula I that can be administered to said subject can range from 0.0001mg to 1000mg. In an embodiment, the compound of formula I can be administered topically as a dermal formulation to a subject in need of treatment for skin disease or complications associated therewith.

[0069] In an embodiment, the skin disease that can be treated by the method disclosed herein can include rosacea, flushing, acne, psoriasis and any inflammatory skin conditions.

[0070] The compounds of the present disclosure may be in the form of hydrates or solvates of acid moiety alpha lipoic acid and the base component represented as X⁺ in which the acid component is in partially ionic form and the base component represented as X⁺ is protonated in the pharmaceutically acceptable salt. In some instances, however, for example depending on the pH of the environment, the compounds may be in the form of a mixture of X⁺ and alpha lipoic acid.

[0071] In certain embodiments, the compounds of the present disclosure may be in the form of hydrates or solvates of acid moiety R-(+)-lipoic acid and the base component represented as X⁺ in which the acid component is in partially ionic form and the base component represented as X⁺ is protonated in the pharmaceutically acceptable salt. In some instances, however, for example depending on the pH of the environment, the compounds may be in the form of a mixture of X⁺ and R-(+)-lipoic acid.

[0072] In many embodiments, the pharmaceutical compositions described herein incorporate the disclosed compound to be delivered in an amount sufficient to deliver to a patient a therapeutically effective amount of a compound of Formula I, as part of a prophylactic or therapeutic treatment. The desired concentration of compound(s) of Formula I or its pharmaceutical acceptable hydrates or solvates will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the hydrates or solvates and compositions from the subject compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.

[0073] Additionally, the optimal concentration and/or quantities or amounts of any particular compound of Formula I may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters may include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition, but not limited thereto.

[0074] The concentration and/or amount of any compound of Formula I may be readily identified by routine screening in animals, e.g., rats, by screening a range of concentration and/or amounts of the material in question using appropriate assays. Known methods are also available to assay local tissue concentrations, diffusion rates of the hydrates or solvates or compositions, and local blood flow before and after administration of therapeutic formulations disclosed herein. One such method is microdialysis, as reviewed by T. E. Robinson et al., 1991, microdialysis in the neurosciences, Techniques, volume 7, Chapter 1. The methods reviewed by Robinson may be applied, in brief, as follows. A microdialysis loop is placed in situ in a test animal. Dialysis fluid is pumped through the loop. When compounds with Formula I such as those disclosed herein are injected adjacent to the loop, released drugs are collected in the dialysate in proportion to their local tissue concentrations. The progress of diffusion of the hydrates or solvates or compositions may be determined thereby with suitable calibration procedures using known concentrations of hydrates or solvates or compositions.

[0075] In certain embodiments, the dosage of the compounds of Formula I provided herein may be determined by reference to the plasma concentrations of the composition or other encapsulated materials. For example, the maximum plasma concentration (C_{max}) and the area under the plasma concentration-time curve from time 0 to infinity may be used.

[0076] Generally, in carrying out the methods detailed in the present disclosure, an effective dosage for the compound of Formula I is in the range of about 0.00001 mg/kg/day to about 100 mg/kg/day in single or divided doses, for instance 0.00001 mg/kg/day to about 50 mg/kg/day in single or divided doses. The compounds of Formulas I may be administered at a dose of, for example, less than 0.0002 mg/kg/day, 0.0005 mg/kg/day, 1.0 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, or 40 mg/kg/day. Compound of Formula I may also be administered to a human patient at a dose of, for example, between 0.001 mg and 1000 mg, between 5 mg and 80 mg, or less than 1.0, 9.0, 12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800,

1000, 2000, 5000 mg per day. In certain embodiments, the compositions herein are administered at an amount that is less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the compound of Formula I required for the same therapeutic benefit.

[0077] A therapeutically effective amount of the compound of Formula I as described herein refers to an amount of the compound of formula I which is sufficient to elicit the desired biological response. An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, halt, restrain, slow or reverse the progression, or reduce the severity of a complication resulting from intraocular pressure, optic nerve complications, glaucoma, ocular lens complications, cataracts, lens thickening and refractive index problems of the eye. As such, these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate. The amount and timing of compositions administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. Thus, because of patient-to-patient variability, the dosages given above are a guideline and the physician may titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases. In an exemplary embodiment, the therapeutically effective amount of the compound of Formula I can range from 0.0001mg to 1000mg.

[0078] A therapeutically effective amount of the compound of Formula I as described herein refers to an amount of the compound of formula I which is sufficient to elicit the desired biological response. An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, halt, restrain, slow or reverse the progression, or reduce the severity of a complication resulting from chronic inflammatory conditions, rosacea, flushing, persistent facial erythema, telangiectasias, papules, pustules, edema, and/or phymatous changes. As such, these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate. The amount and timing of compositions administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. Thus, because of patient-to-patient variability, the dosages given above are a guideline and the physician may

titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases. In an exemplary embodiment, the therapeutically effective amount of the compound of Formula I can range from 0.0001mg to 1000mg.

[0079] The compositions disclosed herein may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, dermal, ocular, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary, but not limited thereto. Further, the compositions may be administered intranasally, as a rectal suppository, or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water. Furthermore, the compositions may be administered to a subject in need of treatment by controlled release dosage forms, site specific drug delivery, transdermal drug delivery, patch (active/passive) mediated drug delivery, by stereotactic injection, or in nanoparticles.

[0080] The compositions may be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents (collectively, referred to herein as excipients), in either single or multiple doses. Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the compounds and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, ointments, topical ophthalmic eye drops, dermal formulations such as cream, ointment, lotions, paste, gel, sprays, solutions, powders, lozenges, syrups, injectable solutions and the likes. These pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the likes. Thus, for purposes of oral administration, tablets containing various excipients such as L-arginine, sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrating agents such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Appropriate materials for this include lactose or milk sugar and high molecular weight

polyethylene glycols, but not limited thereto. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof. The compounds of Formula I may also be formulated as enterically coated formulations including various excipients, as is well known in the pharmaceutical art.

[0081] For parenteral administration, solutions (compositions) may be prepared using (for example) sesame or peanut oil, aqueous propylene glycol, or sterile aqueous solutions. Such solutions may be suitably buffered if necessary, and the liquid diluent is first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

[0082] The formulations, for instance tablets, may contain e.g. 1, 5, 10 to 100, 50 to 250, 150 to 500 mg, or 350 to 800 mg e.g. 10, 50, 100, 300, 500, 700, 800 mg of the compounds of Formula I disclosed herein, for instance, compounds of Formula I or pharmaceutical acceptable hydrates or solvates of a compound of Formula I.

[0083] Generally, a composition as described herein may be administered orally, or parenterally (e.g., intravenous, intramuscular, dermal, topical eye drops, subcutaneous or intramedullary). Topical administration may also be indicated, for example, where the patient is suffering from gastrointestinal disorder that prevent oral administration, or whenever the medication is best applied to the surface of a tissue or organ as determined by the attending physician. Localized administration may also be indicated, for example, when a high dose is desired at the target tissue or organ. For buccal administration the active composition may take the form of tablets or lozenges formulated in a conventional manner.

[0084] The dosage administered will be dependent upon the identity of the disease; the type of host involved, including its age, health and weight; the kind of concurrent treatment, if any; the frequency of treatment and therapeutic ratio, but not limited thereto. Illustratively, dosage levels of the administered active ingredients are: ocular, 0.00001 to about 100mg/kg; dermal, 0.00001 to about 1000mg/kg; intravenous, 0.00001 to about 200 mg/kg; intramuscular, 0.0001 to about

500 mg/kg; orally, 5 to about 1000 mg/kg; intranasal instillation, 5 to about 1000 mg/kg; and aerosol, 5 to about 1000 mg/kg of host body weight.

[0085] Expressed in terms of concentration, an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasally, pharyngolaryngeally, dermal, bronchially, intravaginally, rectally, or ocularly in a concentration of from about 0.00001 to about 50% w/w of the composition; preferably about 1 to about 20% w/w of the composition; and for parenteral use in a concentration of from about 0.00005 to about 50% w/v of the composition and preferably from about 5 to about 20% w/v.

[0086] The compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenteral solutions, suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient. For oral administration either solid or fluid unit dosage forms can be prepared.

[0087] As discussed above, the tablet core may contain one or more hydrophilic polymers. Suitable hydrophilic polymers include, but are not limited to, water swellable cellulose derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, swelling cross-linked polymers, and mixtures thereof. Examples of suitable water swellable cellulose derivatives include, but are not limited to, sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylethylcellulose, and mixtures thereof. Examples of suitable polyalkylene glycols include, but are not limited to, polyethylene glycol. Examples of suitable thermoplastic polyalkylene oxides include, but are not limited to, poly(ethylene oxide). Examples of suitable acrylic polymers include, but are not limited to, potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, high-molecular weight crosslinked acrylic acid homopolymers and copolymers such as those commercially available from Noveon Chemicals under the tradename CARBOPOL™. Examples of suitable hydrocolloids include, but are not limited to, alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan,

tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pustulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and mixtures thereof. Examples of suitable clays include, but are not limited to, smectites such as bentonite, kaolin, and laponite; magnesium trisilicate; magnesium aluminum silicate; and mixtures thereof. Examples of suitable gelling starches include, but are not limited to, acid hydrolyzed starches, swelling starches such as sodium starch glycolate and derivatives thereof, and mixtures thereof. Examples of suitable swelling cross-linked polymers include, but are not limited to, cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellulose sodium, and mixtures thereof.

[0088] The carrier may contain one or more suitable excipients for the formulation of tablets. Examples of suitable excipients include, but are not limited to, fillers, adsorbents, binders, disintegrants, lubricants, glidants, release-modifying excipients, superdisintegrants, antioxidants or mixtures thereof.

[0089] Suitable binders include, but are not limited to, dry binders such as polyvinyl pyrrolidone and hydroxypropylmethylcellulose; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pustulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulose, sucrose, and starches; and mixtures thereof. Suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and mixtures thereof. Suitable lubricants include, but are not limited to, long chain fatty acids and their hydrates or solvates, such as magnesium stearate and stearic acid, talc, glycerides waxes, and mixtures thereof. Suitable glidants include, but are not limited to, colloidal silicon dioxide. Suitable release-modifying excipients include, but are not limited to, insoluble edible materials, pH-dependent polymers, and mixtures thereof.

[0090] Suitable insoluble edible materials for use as release-modifying excipients include, but are not limited to, water-insoluble polymers and low-melting hydrophobic materials, copolymers thereof, and mixtures thereof. Examples of suitable water-insoluble polymers

include, but are not limited to, ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, copolymers thereof and mixtures thereof. Suitable low-melting hydrophobic materials include, but are not limited to, fats, fatty acid esters, phospholipids, waxes, and mixtures thereof. Examples of suitable fats include, but are not limited to, hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil, free fatty acids and their hydrates or solvates, and mixtures thereof. Examples of suitable fatty acid esters include, but are not limited to, sucrose fatty acid esters, mono-, di-, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl triaurylate, glyceryl myristate, GlycoWax-932, lauroyl macrogol-32 glycerides, stearyl macrogol-32 glycerides, and mixtures thereof. Examples of suitable phospholipids include phosphatidyl choline, phosphatidyl serine, phosphatidyl inositol, phosphatidic acid, and mixtures thereof. Examples of suitable waxes include, but are not limited to, carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate, and mixtures thereof. Examples of super disintegrants include, but are not limited to, croscarmellose sodium, sodium starch glycolate and cross-linked povidone (crospovidone). In one embodiment the tablet core contains up to about 5 percent by weight of such super disintegrant.

[0091] Examples of antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid, and edetate hydrates or solvates, and mixtures thereof. Examples of preservatives include, but are not limited to, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid, and mixtures thereof.

[0092] In one embodiment, the immediate release coating has an average thickness of at least 50 microns, such as from about 50 microns to about 2500 microns; e.g., from about 250 microns to about 1000 microns. In embodiment, the immediate release coating is typically compressed at a density of more than about 0.9 g/cc, as measured by the weight and volume of that specific layer.

[0093] In one embodiment, the immediate release coating contains a first portion and a second portion, wherein at least one of the portions contains the second pharmaceutically active agent. In one embodiment, the portions contact each other at a center axis of the tablet. In one embodiment, the first portion includes the first pharmaceutically active agent and the second portion includes the second pharmaceutically active agent.

[0094] In one embodiment, the first portion contains the first pharmaceutically active agent and the second portion contains the second pharmaceutically active agent. In one embodiment, one of the portions contains a third pharmaceutically active agent. In one embodiment one of the portions contains a second immediate release portion of the same pharmaceutically active agent as that contained in the tablet core.

[0095] In one embodiment, the outer coating portion is prepared as a dry blend of materials prior to addition to the coated tablet core. In another embodiment the outer coating portion is included of a dried granulation including the pharmaceutically active agent.

[0096] Formulations with different drug release mechanisms described above could be combined in a final dosage form containing single or multiple units. Examples of multiple units include multilayer tablets, capsules containing tablets, beads, or granules in a solid or liquid form. Typical, immediate release formulations include compressed tablets, gels, films, coatings, liquids and particles that can be encapsulated, for example, in a gelatin capsule. Many methods for preparing coatings, covering or incorporating drugs, are known in the art.

[0097] The immediate release dosage, unit of the dosage form, i.e., a tablet, a plurality of drug-containing beads, granules or particles, or an outer layer of a coated core dosage form, contains a therapeutically effective quantity of the active agent with conventional pharmaceutical excipients. The immediate release dosage unit may or may not be coated, and may or may not be admixed with the delayed release dosage unit or units (as in an encapsulated mixture of immediate release drug-containing granules, particles or beads and delayed release drug-containing granules or beads).

[0098] Extended release formulations are generally prepared as diffusion or osmotic systems, for example, as described in "Remington—The Science and Practice of Pharmacy", 20th. Ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000. A diffusion system typically consists of one of two types of devices, reservoir and matrix, which are well known and described in the

art. The matrix devices are generally prepared by compressing the drug with a slowly dissolving polymer carrier into a tablet form.

[0099] An immediate release portion can be added to the extended release system by means of either applying an immediate release layer on top of the extended release core; using coating or compression processes or in a multiple unit system such as a capsule containing extended and immediate release beads.

[00100] Delayed release dosage formulations are created by coating a solid dosage form with a film of a polymer, which is insoluble in the acid environment of the stomach, but soluble in the neutral or slightly basic environment of small intestine. The delayed release dosage units can be prepared, for example, by coating a drug or a drug-containing composition with a selected coating material. The drug-containing composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a "coated core" dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or capsule.

[00101] A pulsed release dosage form is one that mimics a multiple dosing profile without repeated dosing and typically allows at least a twofold reduction in dosing frequency as compared to the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing, conventional solid dosage form). A pulsed release profile is characterized by a time period of no release (lag time) or reduced release followed by rapid drug release.

[00102] Each dosage form contains a therapeutically effective amount of active agent (compound of formula I). In one embodiment of dosage forms that mimic a twice daily dosing profile, approximately 30 wt. % to 70 wt. %, preferably 40 wt. % to 60 wt. %, of the total amount of active agent in the dosage form is released in the initial pulse, and, correspondingly approximately 70 wt. % to 30 wt. %, preferably 60 wt. % to 40 wt. %, of the total amount of active agent in the dosage form is released in the second pulse. For dosage forms mimicking the twice daily dosing profile, the second pulse is preferably released approximately 3 hours to less than 14 hours, and more preferably approximately 5 hours to 12 hours, following administration.

[00103] Another dosage form contains a compressed tablet or a capsule having a drug-containing immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit. In this dosage form, the immediate release dosage unit contains a

plurality of beads, granules particles that release drug substantially immediately following oral administration to provide an initial dose. The delayed release dosage unit contains a plurality of coated beads or granules, which release drug approximately 3 hours to 14 hours following oral administration to provide a second dose.

[00104] For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, may be prepared.

[00105] Methods of preparing various pharmaceutical compositions with a certain amount of one or more compounds of Formula I and/or other active agents are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).

[00106] In addition, in certain embodiments, subject compositions of the present application maybe lyophilized or subjected to another appropriate drying technique such as spray drying. The subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.

[00107] Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including ophthalmic, dermal, buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of the compound that may be combined with a carrier material/excipient to produce a single dose may vary depending upon the subject being treated, and the particular mode of administration.

[00108] Methods of preparing these formulations or compositions include the step of bringing into association compound with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[00109] The compounds of Formula I described herein may be administered in inhalant or aerosol formulations. The inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy. The final aerosol formulation may for example contain 0.005-90% w/w, for instance 0.005-50%, 0.005-5% w/w, or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.

[00110] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[00111] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject compositions, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, corn, peanut, sunflower, soybean, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[00112] Suspensions, in addition to the active ingredient, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures thereof.

[00113] Dosage forms for transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. A subject composition may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required. For transdermal administration, the complexes may include lipophilic and hydrophilic groups to achieve the desired water solubility and transport properties.

[00114] The ointments, pastes, creams and gels may contain, in addition to subject compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of such substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[00115] Methods of delivering a composition or compositions via a transdermal patch are known in the art. Exemplary patches and methods of patch delivery are described in US Patent Nos. 6,974,588, 6,564,093, 6,312,716, 6,440,454, 6,267,983, 6,239,180, and 6,103,275.

[00116] In another embodiment, a transdermal patch may include: a substrate sheet comprising a composite film formed of a resin composition comprising 100 parts by weight of a polyvinyl chloride-polyurethane composite and 2-10 parts by weight of a styrene-ethylene-butylene-styrene copolymer, a first adhesive layer on the one side of the composite film, and a polyalkylene terephthalate film adhered to the one side of the composite film by means of the first adhesive layer, a primer layer which comprises a saturated polyester resin and is formed on the surface of the polyalkylene terephthalate film; and a second adhesive layer comprising a styrene-diene-styrene block copolymer containing a pharmaceutical agent layered on the primer layer. A method for the manufacture of the above-mentioned substrate sheet comprises

preparing the above resin composition molding the resin composition into a composite film by a calendar process, and then adhering a polyalkylene terephthalate film on one side of the composite film by means of an adhesive layer thereby forming the substrate sheet, and forming a primer layer comprising a saturated polyester resin on the outer surface of the polyalkylene terephthalate film.

[00117] Another type of patch comprises incorporating the drug directly in a pharmaceutically acceptable adhesive and laminating the drug-containing adhesive onto a suitable backing member, e.g. a polyester backing membrane. The drug should be present at a concentration which will not affect the adhesive properties, and at the same time deliver the required clinical dose.

[00118] Transdermal patches may be passive or active. Passive transdermal drug delivery systems currently available, such as the nicotine, estrogen and nitroglycerine patches, deliver small-molecule drugs. Many of the other drugs are too large to be delivered through passive transdermal patches and may be delivered using technology such as electrical assist (iontophoresis) for large-molecule drugs.

[00119] Iontophoresis is a technique employed for enhancing the flux of ionized substances through membranes by application of electric current. One example of an iontophoretic membrane is given in U.S. Pat. No. 5,080,646 to Theeuwes. The principal mechanisms by which iontophoresis enhances molecular transport across the skin are (a) repelling a charged ion from an electrode of the same charge, (b) electroosmosis, the convective movement of solvent that occurs through a charged pore in response the preferential passage of counter-ions when an electric field is applied or (c) increase skin permeability due to application of electrical current.

[00120] Ocular formulations include, but are not limited to, liquid formulations (e.g., solutions, suspensions) for topical administration as well as formulation for injection or ocular insert administration. Preferably, the ocular formulation is formulated for topical administration such as an eye drop, swab, ointment, gel, or mist (for example, an aerosol or spray). In one embodiment, the formulation is an eye drop. For ocular formulations, the pharmaceutically acceptable excipients are selected to be compatible with, and suitable for, ocular use. Such excipients are well known in the art. In one embodiment, excipients may be selected to improve the solubility of the agent. Exemplary excipients include, but are not limited to, buffers, tonicity

agents, viscosity agents, preservatives, emulsifiers, salts, lubricants, polymers, solvents, and other known excipients for ocular pharmaceutical formulations. Appropriate amounts can be determined by one of ordinary skill in the art, but non-limiting exemplary amounts (in % by weight) are also provided below.

[00121] In one embodiment, the pharmaceutical composition includes one or more buffers to adjust or maintain the pH of the formulation. In one embodiment, the pH is near physiological pH (pH of tears is about 7). Thus, the pH of the formulation can be about 6 to about 8, about 6.5 to about 7.5, about 6.8 to about 7.2, about 7.1 to about 7.5, or about 7. In another embodiment, the pH is about 5.5. Thus, the pH of the formulation can be about 4 to about 7, about 4.5 to about 6, about 4.5 to about 5.5, about 5.5 to about 6.5, about 5 to about 6, about 5.25 to about 5.75, or about 5.5. Exemplary buffers include, but are not limited to, phosphate buffers (e.g., sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous), borate buffers, and HBSS (Hank's Balanced Salt Solution). In one embodiment, the buffer is a phosphate buffer. In another embodiment, the buffer is sodium phosphate monobasic monohydrate and/or sodium phosphate dibasic anhydrous. The buffer amount (amount of either total buffer or a single buffer excipient) can be 0.1% to about 1.0%, about 0.2% to about 0.6%, about 0.05% to about 0.5%, about 0.25% to about 0.45%, or about 0.25%, about 0.43%, or about 0.7%. In one embodiment, the buffer is about 0.05% to about 0.5% (e.g., about 0.27%) sodium phosphate monobasic monohydrate and about 0.2% to about 0.6% (e.g., about 0.43%) sodium phosphate dibasic anhydrous.

[00122] In one embodiment, the pharmaceutical composition includes one or more tonicity agents. Although the formulation may be hypertonic or hypotonic, isotonic formulations are preferred (260-320 mOsm). Exemplary tonicity agents include, but are not limited to, sodium chloride. The tonicity agent amount can be about 0.1% to about 5%, about 0.1% to about 2%, about 0.1% to about 1%, about 0.25% to about 0.75%, about 0.2% to about 0.6%, or about 0.5%. In one embodiment, the tonicity agent is about 0.2% to about 0.6% (e.g., about 0.5%) sodium chloride.

[00123] In one embodiment the pharmaceutical composition includes one or more viscosity agents to increase the viscosity of the formulation. Exemplary viscosity agents include, but are not limited to, cellulosic agents (e.g., hydroxypropyl methylcellulose), polycarbophil, polyvinyl

alcohol. In one embodiment, the viscosity agent is a cellulosic agent, e.g., hydroxypropyl methylcellulose. The viscosity agent amount can be about 0.1% to about 5%, about 0.1% to about 2%, about 0.1% to about 1%, about 0.1% to about 0.4%, or about 0.2%. In one embodiment, the viscosity agent is about 0.1% to about 0.4% (e.g., about 0.2%) hydroxypropyl methylcellulose.

[00124] In one embodiment, the pharmaceutical composition includes one or more preservatives to minimize microbial contamination or to enhance shelf life. Exemplary preservatives include, but are not limited to, benzalkonium chloride (BAK), cetrimonium, chlorobutanol, edetate disodium (EDTA), polyquaternium-1 (Polyquad®), polyhexamethylene biguanide (PHMB), stabilized oxychloro complex (PURITE®), sodium perborate, and SofZia®. The preservative amount may be, e.g., less than about 0.02%, about 0.004% or less, or about 0.005% to about 0.01%.

[00125] In one embodiment, the pharmaceutical composition includes one or more stabilizers. Exemplary stabilizers include, but are not limited to amino acids such as alanine. The stabilizer amount can be about 0.1% to about 5%, about 0.1% to about 2%, about 0.1% to about 1%, about 0.25% to about 0.75%, about 0.2% to about 0.6%, or about 0.5%. In one embodiment, the stabilizer is about 0.2% to about 0.6% (e.g., about 0.5%) alanine.

[00126] In one embodiment, the pharmaceutical composition includes one or more emulsifiers. Exemplary emulsifiers include, but are not limited to, Polysorbate 80.

[00127] The compounds described herein can be used in combination with one another, with other active agents known to be useful in ocular disease, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent. For example, adjunctive agents might include one or more amino acids or choline (separate from the lipoic acid compound) to enhance the efficacy of the active agent. The combinations can be advantageous, e.g., in reducing metabolic degradation.

[00128] The term “co-administer” means to administer more than one active agent, such that the duration of physiological effect of one active agent overlaps with the physiological effect of a second active agent. In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Co-administration includes administering two active agents simultaneously, approximately

simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another. In one embodiment, one or more pharmaceutical excipients are selected from the group consisting of buffers, tonicity agents, and viscosity agents.

[00129] The pharmaceutical formulation may be packaged for administration by any means known in the art including, but not limited to, individual dose units or multi-dose units, e.g., dropper bottles. Multi-dose units may include, for example, about 1 mL to about 100 mL, about 1 mL to about 50 mL, about 1 mL to about 10 mL, about 2 mL to about 7 mL, or about 5 mL. An individual dose may be, e.g., 1-10 drops, 1-5 drops, or 2-3 drops, wherein each drop is about 5 to about 50 μ l, about 10 to about 30 μ l, or about 20 μ l. Depending on the active agent concentration and the condition of the patient, doses may be administered.

EQUIVALENTS

[00130] The present disclosure provides among other things compositions and methods for treating eye disorders and skin diseases and their complications. While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the systems and methods herein will become apparent to those skilled in the art upon review of this specification. The full scope of the claimed systems and methods should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.


INCORPORATION BY REFERENCE

[00131] All publications and patents mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

EXAMPLES

[00132] The present disclosure is further explained in the form of following examples. However, it is to be understood that the examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.

[00133] EXAMPLE-1: Synthesis of 2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro-1H-imidazol-1-ium 5-(1,2-dithiolan-3-yl)pentanoate [CLX-SYN-G162]



Stage-1: Preparation of Brimonidine free base:

Brimonidine tartrate (20 g, 45.25 mmol) was added into water (400 mL) in a 1.0 L 3-necked RB flask and stirred for 30 min at room temperature. Sodium carbonate (9.6 g, 90.5 mmol) was added lot wise to the homogeneous solution of Brimonidine tartrate and allowed to stir for about 2-3 h. The reaction mixture was cooled to 10-15 °C, filtered the solid and the filter cake was washed with water (3 x 100 mL). The yellow color solid obtained was suck dried for 3-4 h and then dried in hot air oven at 50-55 °C for about 6-8 h.

Yield: 23.0 g, Yellow solid

% Yield: 87.2

Purity by HPLC: 99.98%

MS: m/z 294 [M+2H]⁺

¹H NMR (400 MHz, DMSO-*d*₆): δ 3.4 (s, 4H), 6.5 (s, 2H), 7.56 (d, 1H, *J* = 9.2 Hz), 7.83 (d, 1H, *J* = 9.2 Hz), 8.68 (d, 1H, *J* = 2 Hz), 8.84 (d, 1H, *J* = 2 Hz).

¹³C NMR (100 MHz, DMSO-*d*₆): δ 41.8, 114.1, 127.8, 128.8, 139.2, 141.7, 141.9, 145.1, 152.5, 158.1.

Stage-2: Synthesis of CLX-SYN-G162:


Alpha Lipoic acid (10.6 g, 51.3 mmol.) was dissolved in Isopropanol (100 mL) in a 250 ml 3-Necked RB flask at 25-30 °C. Brimonidine free base (10 g, 34 mmol.) was added to the reaction mixture and stirred at room temperature (25-30 °C) for 2 h. The solid obtained was filtered and washed with Isopropanol (30 mL). The pale yellow solid obtained was suck dried for 3-4 h and further dried in hot air oven at 45-50 °C for 5h.

Yield: 15 g, Pale yellow solid

% Yield: 88.0

IR (cm⁻¹): 2947.9, 2900.26, 2665.0, 1671.4, 1601.8, 1036.8

¹H NMR (400 MHz, DMSO-*d*₆) δ : 1.35-1.40 (m, 2H), 1.47-1.57 (m, 3H), 1.62-1.69 (m, 1H), 1.84-1.89 (m, 1H), 2.20 (t, 2H, *J* = 7.2 Hz), 2.38-2.45 (m, 1H), 3.11-3.20 (m, 2H), 3.39 (s, 4H), 3.57-3.63 (m, 1H), 6.56 (brs, 2H), 7.56 (d, 1H, *J* = 8.8 Hz), 7.83 (d, 1H, *J* = 8.8 Hz), 8.69 (s, 1H), 8.84 (s, 1H), 12.0 (Br, 1H).



¹³C NMR (100 MHz): 25.5, 29.2, 34.8, 35.8, 38.6, 40.4, 43.0, 56.7, 119.3, 129.5, 129.7, 141.3, 141.7, 144.1, 145.5, 159.5, 179.7

Solvent: CDCl₃

Position of the Carbon atom	Chemical shift, ppm
CH ₂ carbon of lipoic acid (C1)	δ 25.5
CH ₂ carbon of lipoic acid (C2)	δ 29.2
CH ₂ carbon of lipoic acid (C3)	δ 34.8
CH ₂ carbon of lipoic acid (C4)	δ 35.8
CH ₂ carbon of lipoic acid ring (C5)	δ 38.6
CH ₂ Carbon of lipoic acid ring (C6)	δ 40.4


CH ₂ Carbon on dihydroimidazole ring (C7-C8)	δ 43.0
CH-Chiral carbon of lipoic acid (C9)	δ 56.7
C-Br of Brimonidine ring (C10)	δ 119.3
CH-Carbon on aromatic ring (C11)	δ 129.5
CH-Carbon on aromatic ring (C12)	δ 129.7
CH-Carbon on quinoxaline ring (C13)	δ 141.3
CH-Carbon on quinoxaline ring (C14)	δ 141.7
Bridge carbon of Brimonidine ring (C15)	δ 144.1
Bridge carbon of Brimonidine ring (C16) and Carbon on Brimonidine ring (C17)	δ 145.4
Carbon between two nitrogens of dihydroimidazole ring (C18)	δ 159.5
C=O of Lipoic acid (C19)	δ 179.7

Purity by HPLC: 99.99% (Area %)

Purity by Assay:

Individual component	Theoretical contribution	CLX-SYN-G162
Brimonidine	58.6%	61.40
Lipoic acid	41.4%	38.15


[00134] **EXAMPLE-2: Synthesis of (R)-5-(1,2-dithiolan-3-yl)pentanoate3-acetoxyquinuclidin-1-ium (CLX-G162-C01):**



To a stirred solution of (R)-5-(1,2-dithiolan-3-yl)pentanoic acid **1** (2.4 g, 11.63 mmol) in DCM (50 mL) was added quinuclidin-3-yl acetate **2** (1.97 g, 11.63 mmol) at ambient temperature. The resulting reaction mixture was stirred at same temperature for next 4h followed by the evaporation of solvent under reduced pressure to get the desired product (**CLX-G162-C01**) as viscous liquid. Yield: 4.37 g, quantitative.

¹H-NMR spectrum of Compound CLX-G162-C01 is shown in FIGs. 1 to 3.


[00135] EXAMPLE-3: Synthesis of (R)-5-(1,2-dithiolan-3-yl)pentanoic acid N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide (CLX-G162-C02):



To a stirred solution of (R)-5-(1,2-dithiolan-3-yl)pentanoic acid **1** (1.70 g, 8.24 mmol) in DCM (50 mL) was added N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide **3** (2.34 g, 8.24 mmol) at room temperature. The resulting reaction mixture was stirred at same temperature for next 4h followed by the evaporation of solvent under reduced pressure to get the desired product (**CLX-G162-C02**) as viscous liquid. Yield 4.04 g, quantitative.

¹H-NMR spectrum of Compound CLX-G162-C02 is shown in FIGs. 4 to 6.


[00136] **EXAMPLE-4: Synthesis of (R)-5-(1,2-dithiolan-3-yl)pentanoate-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazol-1-ium (CLX-G162-C03):**



To a stirred solution of (R)-5-(1,2-dithiolan-3-yl)pentanoic acid **1** (2.1 g, 10.18 mmol) in DCM (50 mL) was added 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole **4** (2.04 g, 9.7 mmol) at room temperature. The resulting reaction mixture was stirred at same temperature for next 4h followed by the evaporation of solvent under reduced pressure to get the desired product (**CLX-G162-C03**) as viscous liquid. Yield: 4.14 g, quantitative.

¹H-NMR spectrum of Compound CLX-G162-C03 is shown in FIGs. 7 to 9.

[00137] **EXAMPLE-5: Synthesis of 2-((5-bromoquinoxalin-6-yl)amino)-4,5-dihydro-1H-imidazol-1-ium (R)-5-(1,2-dithiolan-3-yl)pentanoate (CLX-SYN-G162-1):**



Stage-01: Preparation of Brimonidine free base:

Brimonidine tartrate (20 g, 45.25 mmol) was added into water (400 mL) in a 1.0 L 3-necked RB flask placed in a water bath. The mixture was stirred for 30 min at room temperature (25-30 °C). Sodium carbonate (9.6 g, 90.5 mmol) was added in 3 lots (Lot-1: 3.0 g, Lot-2: 3.0 g and Lot-3: 3.6 g) to the homogeneous solution of Brimonidine tartrate, keeping the internal

temperature at 25-30 °C (Note: No exotherm was observed during the addition of sodium carbonate). The resulting mixture was allowed to stir for about 2-3 h at 25-30 °C. The reaction mixture was cooled to 10-15 °C, filtered the solid and the filter cake was washed with water (3 x 100 mL). The yellow color solid obtained was suck dried for 3-4 h and then dried in hot air oven at 50-55 °C for about 6-8 h.

Yield: 23.0 g, Yellow solid

% Yield: 87.2

M.P.: 255--257 °C


MS: m/z 294 [M+H+2]⁺

IR (cm-1): 3161, 2941, 2870, 1649, 1594, 707

Position of the Functional group	Wave number (cm-1)
NH group on dihydroimidazole ring, NH group between 5-Bromo quinoxaline and dihydroimidazole ring	3161
CH-Stretching of dihydroimidazole ring	2941
CH- aromatic ring	2870
C=C Stretching	1649
C=N Stretching	1594
C-Br stretching of aromatic ring	707

¹H NMR (400 MHz, DMSO-d₆): δ 3.4 (s, 4H, Ha and Hb), 6.56 (s, 2H, Hc and Hd), 7.56 (d, 1H, J = 9.2 Hz, He), 7.83 (d, 1H, J = 9.2 Hz, Hf), 8.68 (d, 1H, J = 2 Hz, Hg), 8.84 (d, 1H, J = 2 Hz, Hf).

¹H NMR (400 MHz)




Solvent: DMSO-d₆

Position of the proton	Chemical shift, δ with multiplicity
------------------------	-------------------------------------

CH2 Protons on dihydroimidazole ring (Ha-Hb)	δ 3.4 (4H, s)
NH Proton on dihydroimidazole ring (Hc), NH proton between 5-Bromo quinoxaline and dihydroimidazole ring (Hd)	δ 6.56 (2H, brs)
CH-Proton of aromatic ring (He)	δ 7.56 (1H, d, J = 9.2 Hz)
CH-Proton of aromatic ring (Hf)	δ 7.83 (1H, d, J = 9.2 Hz)
CH-Proton on Pyrazine ring (Hg)	δ 8.68 (1H, d, J = 2.0 Hz)
CH-Proton on Pyrazine ring (Hh)	δ 8.84 (1H, d, J = 2.0 Hz)

¹³C NMR (100 MHz): δ 41.8, 114.1, 127.8, 128.8, 139.2, 141.7, 141.9, 145.1, 152.5, 158.1.



Solvent: DMSO-d₆

Position of the Carbon atom	Chemical shift, ppm
CH2 Carbon on dihydroimidazole ring (C1-C2)	δ 41.8
Carbon on aromatic ring (C3)	δ 114.1
CH-Carbon on aromatic ring (C4)	δ 127.8
CH-Carbon on aromatic ring (C5)	δ 128.8
CH-Carbon on aromatic ring (C6)	δ 139.2
CH-Carbon on aromatic ring (C7)	δ 141.7
CH-Carbon on aromatic ring (C8)	δ 141.9
CH-Carbon on aromatic ring (C9)	δ 145.1
CH-Carbon on aromatic ring (C10)	δ 152.5
CH-Carbon on aromatic ring (C11)	δ 158.1

Purity by HPLC: 99.98%

Stage-02: Synthesis of CLX-SYN-G162-1:

R-(+)-Lipoic acid (2.54 g, 12.32 mmol) was dissolved in Isopropanol (30 mL) in a 250 ml 3-Necked RB flask at 25-30 °C. Brimonidine free base (3.0 g, 10.27 mmol) was added to the reaction mixture in one lot [Note: No exotherm was observed after addition of Brimonidine]. The reaction mixture was stirred at room temperature (25-30 °C) for 2 h. The solid obtained was filtered and washed with Isopropanol (15 mL). The pale yellow solid obtained was suck dried for 3-4 h and further dried in hot air oven at 40-45 °C for 5 h.

Yield: 4.2 g, Pale yellow solid

% Yield: 82.35

M.P.: 161.2-236.6 °C

Specific Optical Rotation [α]D 25 (c = 0.5, Methanol): 48.4 °

LCMS: m/z 294 [M+H+2]⁺ Molecular ion of Brimonidine

m/z 413 [2M+H]⁺ Dimer of R-(+)-Lipoic acid

m/z 251 [M+45]⁺ : Formic acid adduct of R-(+)-Lipoic acid (M+HCOO⁻)

m/z 229 [M+23]⁺ : Sodium adduct of R-(+)-Lipoic acid


m/z 189 [M-17]⁺ : R-(+)-Lipoic acid- OH (Loss of hydroxyl group from R-(+)-Lipoic acid)

m/z 160.9 [M-45+H]⁺ : Loss of carboxylic acid from R-(+)-Lipoic acid (M-COOH)

IR (cm⁻¹): 2949, 2903, 1673, 1602, 705


Position of the Functional group	Wave number (cm ⁻¹)
NH group on dihydroimidazole ring, NH group between 5-Bromo quinoxaline and dihydroimidazole ring	2949
CH- aromatic ring	2903
C=C Stretching	1673
C=N Stretching	1602
C-Br stretching of aromatic ring	705

¹H NMR (400 MHz):



¹H NMR (400 MHz, CDCl₃): 1.48-1.57 (m, 2H), 1.65-1.70 (m, 4H), 1.86-1.95 (m, 1H), 2.29 (t, 2H, J = 7.2 Hz), 2.43-2.49 (m, 1H), 3.07-3.18 (m, 2H), 3.20-3.61 (m, 1H), 3.70 (s, 4H), 4.98 (brs, 4H), 7.60 (d, 1H, J = 9.2 Hz), 7.94 (d, 1H, J = 9.2 Hz), 8.75 (s, 1H), 8.87 (s, 1H).


¹H NMR (400 MHz, CDCl₃ -D₂O exchange): 1.42-1.56 (m, 2H), 1.63-1.73 (m, 4H), 1.86-1.95 (m, 1H), 2.30 (t, 2H, J = 7.2 Hz), 2.41-2.49 (m, 1H), 3.07-3.20 (m, 2H), 3.54-3.59 (m, 1H), 3.61 (s, 4H), 7.59 (d, 1H, J = 9.2 Hz), 7.94 (d, 1H, J = 9.2 Hz), 8.74 (s, 1H), 8.87 (s, 1H).



¹³C NMR (100 MHz): 25.5, 29.2, 34.9, 35.9, 38.6, 40.4, 43.1, 56.7, 119.7, 129.4, 129.8, 141.2, 141.4, 144.2, 144.6, 145.5, 159.7, 179.8.

We Claim:






1. A compound of formula I:








Formula I


or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,


wherein, X^+ represents,












2. The compound as claimed in claim 1, which is a compound of formula Ia:




Formula Ia

or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein X^+ is as defined in claim 1.

3. The compound as claimed in claim 1, which is a compound of formula Ib:



Formula Ib

or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof,

wherein X^+ is as defined in claim 1.

4. A pharmaceutical composition comprising as an active ingredient at least one compound as claimed in any one of claims 1 to 3 or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
5. The pharmaceutical composition as claimed in claim 4, further comprising at least one pharmaceutically acceptable excipient.
6. The pharmaceutical composition as claimed in claim 4, wherein said composition is formulated for oral, nasal, dermal, ocular, topical, rectal, vaginal, aerosol or parenteral administration.
7. The pharmaceutical composition as claimed in claim 4, wherein said composition is for treatment of an eye disorder, skin disease or a complication thereof.
8. A method of treating an eye disorder or a complication thereof in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of at least one compound as claimed in any one of claims 1 to 3 or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
9. The method as claimed in claim 8, wherein said at least one compound is administered to said subject in combination with at least one pharmaceutically acceptable excipient.
10. The method as claimed in claim 8, wherein said eye disorder is selected from the group consisting of macular degeneration, cataract, ocular graft versus host disease (oGVHD), glaucoma, diabetic retinopathy, dry eye, ocular redness, ocular irritation, ocular neuritis, retinitis pigmentosa and presbyopia.


11. A method of treating a skin disease or a complication thereof in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of at least one compound as claimed in any one of claims 1 to 3 or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, polymorph or prodrug thereof.
12. The method as claimed in claim 11, wherein said at least one compound is administered to said subject in combination with at least one pharmaceutically acceptable excipient.
13. The method as claimed in claim 11, wherein said skin disease is selected from the group consisting of rosacea, dermatitis, flushing, acne, psoriasis and inflammatory skin conditions.

J992-A01133-045


DMSO

2.312
 2.190
 2.174
 2.166
 2.144
 2.127
 2.110
 2.100
 2.088
 2.033
 2.016
 2.005
 2.010
 2.007
 2.004
 2.004
 2.016
 1.891
 1.874
 1.859
 1.842
 1.810
 1.694
 1.680
 1.662
 1.647
 1.585
 1.574
 1.554
 1.535
 1.512
 1.496
 1.479
 1.405
 1.386
 1.368
 1.347

CLX-G162-C01



CLX-G162-C01 (J992-A01133-045)



```

NAME: J992-A01133-045
EXPNO: 2
PROCNO: 1
DATE_: 20180514
TIME: 17.23
INSTRUM: spect
PROBHD: 5mmQNP1H1
PULPROG: zgpg30
TD: 65536
SOLVENT: DMSO
DMSO: 300
AQ: 0.19544800
RG: 320.00
DS: 4.00000000
SWH: 12.00000000
F2: 125.761
AQ: 0.19544800
RG: 320.00
DS: 4.00000000
SWH: 12.00000000
F2: 125.761
AQ: 0.19544800
RG: 320.00
DS: 4.00000000
SWH: 12.00000000
F2: 125.761
  
```

FIG.1




FIG. 2






FIG. 3



J992-A01133-043

DMSO

CLX-G162-C03



CLX-G162-C03 (J992-A01133-043)

7.033
3.761
3.623
3.606
3.589
3.543
3.502
3.489
3.474
3.660
3.538
3.216
3.167
3.126
3.109
3.098
3.081
2.791
2.741
2.739
2.500
2.403
2.418
2.402
2.387
2.377
2.187
2.169
2.151
2.137
1.917

Chemical Shift (ppm)	Integration
7.033	4.00
3.761	1.13
3.623	0.94
3.606	4.31
3.589	3.03
3.543	4.01
3.502	0.91
3.489	2.26
3.474	2.17
3.660	1.20
3.538	3.06
3.216	2.12
3.167	0.88
3.126	
3.109	
3.098	
3.081	
2.791	
2.741	
2.739	
2.500	
2.403	
2.418	
2.402	
2.387	
2.377	
2.187	
2.169	
2.151	
2.137	
1.917	





FIG. 7

J992-A01133-043


DMSO

7.125
7.109
7.102
7.093
7.083
7.074
7.068

CLX-G162-C03



CLX-G162-C03 (J992-A01133-043)




Chemical Shift (ppm)	Integration
7.125	0.00
7.109	0.00
7.102	0.00
7.093	0.00
7.083	0.00
7.074	0.00
7.068	0.00
7.000	4.00

FIG. 8

J992-A01133-043

DMSO

CLX-G162-C03



NAME	J992-A01133-043
EXPNO	1
F2PROC0	0
PROCNO	1
DATE_	20180514
TIME	17.58.5
INSTRUM	ggc01
PROBHD1	5mmQNP1H
PULPROG	zgpg30
TD	65536
SF	400.146
WDW	EM
SSB	0
LB	3.00
GB	0
PC	1.00
RG	327.50
ACQ	2.1562000000000000
DELTA	199.93
DELTA2	40.000000000000000
DELTA3	15.000000000000000
DELTA4	0.0000000000000000
TD0	1
SI	400.146000000000000
NUC1	1H
NUC2	13C
NUC3	15N
NUC4	19F
WALTZ	0
WALTZ2	0
WALTZ3	0
WALTZ4	0
WALTZ5	0
WALTZ6	0
WALTZ7	0
WALTZ8	0
WALTZ9	0
WALTZ10	0
WALTZ11	0
WALTZ12	0
WALTZ13	0
WALTZ14	0
WALTZ15	0
WALTZ16	0
WALTZ17	0
WALTZ18	0
WALTZ19	0
WALTZ20	0
WALTZ21	0
WALTZ22	0
WALTZ23	0
WALTZ24	0
WALTZ25	0
WALTZ26	0
WALTZ27	0
WALTZ28	0
WALTZ29	0
WALTZ30	0
WALTZ31	0
WALTZ32	0
WALTZ33	0
WALTZ34	0
WALTZ35	0
WALTZ36	0
WALTZ37	0
WALTZ38	0
WALTZ39	0
WALTZ40	0
WALTZ41	0
WALTZ42	0
WALTZ43	0
WALTZ44	0
WALTZ45	0
WALTZ46	0
WALTZ47	0
WALTZ48	0
WALTZ49	0
WALTZ50	0
WALTZ51	0
WALTZ52	0
WALTZ53	0
WALTZ54	0
WALTZ55	0
WALTZ56	0
WALTZ57	0
WALTZ58	0
WALTZ59	0
WALTZ60	0
WALTZ61	0
WALTZ62	0
WALTZ63	0
WALTZ64	0
WALTZ65	0
WALTZ66	0
WALTZ67	0
WALTZ68	0
WALTZ69	0
WALTZ70	0
WALTZ71	0
WALTZ72	0
WALTZ73	0
WALTZ74	0
WALTZ75	0
WALTZ76	0
WALTZ77	0
WALTZ78	0
WALTZ79	0
WALTZ80	0
WALTZ81	0
WALTZ82	0
WALTZ83	0
WALTZ84	0
WALTZ85	0
WALTZ86	0
WALTZ87	0
WALTZ88	0
WALTZ89	0
WALTZ90	0
WALTZ91	0
WALTZ92	0
WALTZ93	0
WALTZ94	0
WALTZ95	0
WALTZ96	0
WALTZ97	0
WALTZ98	0
WALTZ99	0
WALTZ100	0

FIG. 9